[go: up one dir, main page]

AU3245593A - Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone - Google Patents

Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone

Info

Publication number
AU3245593A
AU3245593A AU32455/93A AU3245593A AU3245593A AU 3245593 A AU3245593 A AU 3245593A AU 32455/93 A AU32455/93 A AU 32455/93A AU 3245593 A AU3245593 A AU 3245593A AU 3245593 A AU3245593 A AU 3245593A
Authority
AU
Australia
Prior art keywords
disorders
zopiclone
compositions
methods
optically pure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32455/93A
Inventor
Steven Brandt
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU3245593A publication Critical patent/AU3245593A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU32455/93A 1991-12-02 1992-12-01 Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone Abandoned AU3245593A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80131291A 1991-12-02 1991-12-02
US801312 1991-12-02

Publications (1)

Publication Number Publication Date
AU3245593A true AU3245593A (en) 1993-06-28

Family

ID=25180769

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32455/93A Abandoned AU3245593A (en) 1991-12-02 1992-12-01 Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone

Country Status (2)

Country Link
AU (1) AU3245593A (en)
WO (1) WO1993010787A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339086B1 (en) 1999-05-14 2002-01-15 Swpracor, Inc. Methods of making and using N-desmethylzopiclone
CA2557850A1 (en) 2004-04-05 2005-10-20 Sepracor Inc. Methods of treatment using eszopiclone
US7465729B2 (en) 2004-04-05 2008-12-16 Sepracor Inc. Methods of treatment of menopause and perimenopause using eszopiclone
US8268832B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
WO2009085988A1 (en) * 2007-12-19 2009-07-09 Sepracor Inc. Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7- dihydro-5h-pyrrolo[3,4-b]pyrazine
US8269005B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CA2812705C (en) * 2007-12-19 2015-08-18 Sunovion Pharmaceuticals Inc. Maleate, besylate and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine
JP2012516348A (en) 2009-01-30 2012-07-19 サノビオン ファーマシューティカルズ インク Of 6- (5-chloro-2-pyridyl) -5-[(4-methyl-1-piperazinyl) carbonyloxy] -7-oxo-6,7-dihydro-5H-pyrrolo [3,4-b] pyrazine Coated tablet and method for measuring the effect of coating

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA04285A (en) * 1972-01-07 1979-12-31 Rhone Poulenc Sa New derivatives of pyrrolo (3,4-b) pyrazine and their preparation.

Also Published As

Publication number Publication date
WO1993010787A1 (en) 1993-06-10

Similar Documents

Publication Publication Date Title
AU6904498A (en) Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
AU7039896A (en) Methods and compositions for treating emesis, nausa and other disorders using optically pure R(+) ondansetron
AU2187992A (en) Composition and method for disease treatment
AU7577994A (en) Methods for inhibiting bone loss
AU2113295A (en) Novel compositions and methods for water treatment
AU7540591A (en) Sludge treatment process
AU5359490A (en) Eyewear retainer
AU3245593A (en) Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (+) zopiclone
AU5652698A (en) (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors
AU5317296A (en) Methods for treating conditions associated with excess nitri c oxide
AU7249494A (en) Method for increasing the capacity of sewage treatment plant
AU6993998A (en) Methods and compositions for treating asthma, atherosclerosis and inflammatory diseases using optically pure (-)-zileuton
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU3275993A (en) Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone
AU7018794A (en) Methods for treating pathologies
AU1175692A (en) Effluent treatment
AU1658992A (en) Methods and compositions for treating pulmonary disorders using optically pure terbutaline
AU5546694A (en) Process for optically pure decahydroisoquinolines
AU1578795A (en) Enantiomerically pure (+)-liarozole
AU3974495A (en) Optical treatment method
AU2221497A (en) Methods and compositions for treating hypertension, angina, and other disorders using optically pure S(-) felodipine
AU6904598A (en) Methods and compositions for treating gastric disorders using optically pure (+) pantoprazole
AU1515197A (en) Methods and compositions for treating infection using optically pure (S)-lomefloxacin
AU2003204192A1 (en) Methods and Compositions for Treating Gastric Disorders Using Optically Pure (-) Pantoprazole
AU1628488A (en) Compositions for treating contact lenses